Skip to main content

drug development Archives

Treating kidney injury before it happens

May. 23, 2023—Pretreatment of an animal model with a novel compound called PHAD reduced kidney injury, suggesting it may be a good candidate for preventing kidney injury in surgical patients.

Read more


A speedier treatment for depression?

Jul. 11, 2022—Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.

Read more


Clinical study tests drug that may prevent cancer metastasis

Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Read more


The arrestin-GPCR connection

Apr. 11, 2019—Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.

Read more


Regulating anxiety in the brain

Apr. 28, 2017—Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both.

Read more


Protein structure may aid in treating Alzheimer’s disease

Apr. 27, 2017—A new protein structure may guide the development of Alzheimer's therapeutics.

Read more


New type of trial shows promise for several cancers

Aug. 20, 2015—Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more